C-reactive protein and procalcitonin in the evaluation of the efficacy of a pneumococcal conjugate vaccine in Gambian children
- 6 March 2008
- journal article
- research article
- Published by Wiley in Tropical Medicine & International Health
- Vol. 13 (5), 603-611
- https://doi.org/10.1111/j.1365-3156.2008.02050.x
Abstract
To determine the value of C-reactive protein (CRP) and procalcitonin in the evaluation of the efficacy of a pneumococcal conjugate vaccine in Gambian children. The investigation was done as a substudy of a phase III pneumococcal conjugate vaccine trial. A pilot study (n = 120) to compare CRP and procalcitonin concentrations in children with pneumonia was undertaken, followed by a larger study of CRP concentrations (n = 1868) obtained from a subsample of children with clinical pneumonia seen during the trial. In the pilot study, CRP had a higher sensitivity and specificity for the detection of primary endpoint (radiographic) pneumonia than procalcitonin. In the subsequent study of 1868 episodes of clinical pneumonia, CRP showed moderate sensitivity but poor positive predictive value in identifying primary endpoint pneumonia or pneumococcal bacteraemia. Addition of CRP thresholds of 40, 60 or 120 mg/l to the diagnosis of clinical pneumonia did not give higher estimates of vaccine efficacy or vaccine attributable reduction in incidence than primary endpoint pneumonia. A combination of a raised CRP concentration with a clinical diagnosis of pneumonia is a more specific endpoint than clinical pneumonia alone but less appropriate than primary endpoint pneumonia as a measure of the impact of a pneumococcal vaccine in a Gambian setting.Keywords
This publication has 17 references indexed in Scilit:
- Epidemiology and clinical features of pneumonia according to radiographic findings in Gambian childrenTropical Medicine & International Health, 2007
- World Health Organisation definition of “radiologically-confirmed pneumonia” may under-estimate the true public health value of conjugate pneumococcal vaccinesVaccine, 2007
- Effectiveness of Heptavalent Pneumococcal Conjugate Vaccine in Children Younger Than 5 Years of Age for Prevention of PneumoniaThe Pediatric Infectious Disease Journal, 2006
- Operational Challenges in Large Clinical Trials: Examples and Lessons Learned from the Gambia Pneumococcal Vaccine TrialPLoS Clinical Trials, 2006
- Efficacy of nine-valent pneumococcal conjugate vaccine against pneumonia and invasive pneumococcal disease in The Gambia: randomised, double-blind, placebo-controlled trialThe Lancet, 2005
- Use of Procalcitonin and C-Reactive Protein to Evaluate Vaccine Efficacy against PneumoniaPLoS Medicine, 2005
- A Trial of a 9-Valent Pneumococcal Conjugate Vaccine in Children with and Those without HIV InfectionThe New England Journal of Medicine, 2003
- Efficacy, safety and immunogenicity of heptavalent pneumococcal conjugate vaccine in childrenThe Pediatric Infectious Disease Journal, 2000
- The epidemiology of pneumococcal infection in children in the developing worldPhilosophical Transactions Of The Royal Society B-Biological Sciences, 1999
- Users' Guides to the Medical LiteratureJAMA, 1994